Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-CART-007 in relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
NL-OMON53869Phase 2Active, not recruiting
- Sponsor
- Wugen
- Start
- Oct 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of soficabtagene geleucel in t-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL), sponsored by Wugen. Primary endpoints: Safety and tolerability, Recommended Phase 2 Dose and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
soficabtagene geleucel
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NL-OMON53869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53869.